Ossio has successfully closed a $38.5 million Series C financing round led by MVM Partners to expand its innovative OSSIOfiber Intelligent Bone Regeneration Technology in the U.S. orthopedic market.
Information on the Target
Ossio is an innovative company specializing in orthopedic fixation technology, known for its OSSIOfiber Intelligent Bone Regeneration Technology. Recently, Ossio announced that it has successfully closed $38.5 million in Series C financing, enabling the company to further propel its growth and market presence. This funding round was led by MVM Partners, a growth equity firm based in Boston and London, with additional participation from OCV Partners.
The OSSIOfiber technology represents a significant advancement in fixation materials, addressing the limitations associated with traditional permanent metal hardware and other types of implants. This groundbreaking product combines exceptional mechanical strength with the natural healing capabilities of bone, offering surgeons a temporary solution that fosters better patient outcomes.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The orthopedic fixation market in the United States is an expansive and rapidly evolving segment of the healthcare industry, valued in the billions of dollars. With an increasing aging population and a rising incidence of
Similar Deals
Harel Insurance & Finance, European Innovation Council (EIC) Fund → Omnix Medical
2025
MVM Partners
invested in
Ossio
in
in a Other deal
Disclosed details
Transaction Size: $39M